| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
38,129 |
29,721 |
$9.41M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
25,056 |
22,062 |
$252K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16,043 |
13,361 |
$241K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,116 |
2,975 |
$129K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,132 |
5,121 |
$114K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,452 |
1,412 |
$86K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
4,203 |
4,159 |
$84K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,327 |
2,316 |
$67K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,028 |
1,002 |
$54K |
| 92552 |
|
5,491 |
5,461 |
$54K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,137 |
1,131 |
$49K |
| J3490 |
Unclassified drugs |
6,128 |
6,096 |
$43K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,084 |
1,076 |
$39K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,709 |
4,688 |
$34K |
| 87486 |
|
2,543 |
2,449 |
$33K |
| 87581 |
|
2,542 |
2,448 |
$32K |
| G0071 |
Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only |
712 |
686 |
$17K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
124 |
122 |
$10K |
| 99383 |
|
134 |
133 |
$10K |
| 86580 |
|
5,331 |
5,309 |
$10K |
| 99173 |
|
5,340 |
5,310 |
$9K |
| 99384 |
|
100 |
97 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,553 |
1,538 |
$8K |
| 99000 |
|
3,866 |
3,714 |
$8K |
| 99382 |
|
98 |
98 |
$7K |
| 85018 |
|
5,749 |
5,722 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,384 |
1,363 |
$6K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,259 |
1,229 |
$5K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
7,356 |
7,283 |
$3K |
| 90461 |
|
4,390 |
4,379 |
$3K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
36 |
36 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
153 |
142 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
466 |
452 |
$1K |
| 0250 |
|
126 |
122 |
$1K |
| 83655 |
|
146 |
146 |
$945.89 |
| 0259 |
|
75 |
73 |
$809.54 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
12 |
12 |
$615.72 |
| 99201 |
|
15 |
15 |
$502.35 |
| 81003 |
|
275 |
261 |
$379.03 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
95 |
91 |
$282.20 |
| 81001 |
|
176 |
169 |
$252.44 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
13 |
13 |
$225.00 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13 |
12 |
$204.75 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
66 |
64 |
$6.29 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
322 |
320 |
$0.00 |
| 90677 |
|
23 |
23 |
$0.00 |
| 99381 |
|
42 |
42 |
$0.00 |
| 90697 |
|
20 |
20 |
$0.00 |
| 99441 |
|
73 |
69 |
$0.00 |
| Z7610 |
|
26 |
26 |
$0.00 |
| 90680 |
|
17 |
17 |
$0.00 |